Overview
Brooklyn Health builds Willis, an electronic Clinical Outcome Assessment (eCOA) platform for CNS clinical trials that uses AI and digital phenotyping to derive objective measurements from clinical interviews by analyzing spoken words, facial expressions, body language, and voice tone. The platform is organized into OpenWillis (an open-source library of digital phenotyping methods), WillisPipeline (which converts behavioral data into clinical measures), and WillisAPI (for integrating with other digital health tools). It differentiates itself by providing validated, standardized digital measures that reduce bias and help distinguish drug effects from placebo in trials conducted with major pharma partners like Bristol Myers Squibb and Boehringer Ingelheim. Brooklyn Health’s goal is to improve the accuracy of treatment evaluation in CNS trials and lower failure rates in CNS drug development.
Work here?Claim your company
Simplify's take
What believers are saying
- Brooklyn Health raised $6.5 million in May 2025, funding hiring and deployments.
- Willis Academy launched in October 2026, expanding low-cost rater training and lead generation.
- The October 2026 website claims near-real-time validation and multiple global clinical programs.
What critics are saying
- Bristol Myers Squibb and Boehringer Ingelheim validation is unproven commercial revenue, not durable demand.
- If regulators reject AI-scored endpoints, Willis becomes a costly workflow tool by 2027.
- Open-source methods and incumbents like Medidata can commoditize Brooklyn Health’s measurement advantage.
What makes Brooklyn Health unique
- WillisAI reviews 100% of CNS interviews, replacing subjective rater-only endpoint scoring.
- Brooklyn Health combines OpenWillis, WillisPipeline, and WillisAPI into one measurement stack.
- Anzar Abbas brings Cambridge Cognition and AiCure digital-biomarker experience to Brooklyn Health.
Help us improve and share your feedback! Did you find this helpful?